Atara Biotherapeutics Under Investigation After 57% Stock Drop Following FDA Response
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
Should l Buy ATRA?
Source: PRnewswire
- FDA Response Impact: On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter for the EBVALLO™ Biologics License Application, indicating that the application cannot be approved in its current form, resulting in a stock price drop of $7.79, or 56.99%.
- Clinical Trial Issues: The FDA stated that Atara's single-arm ALLELE trial is no longer considered adequate to support accelerated approval, with design and analysis flaws rendering the results difficult to interpret, directly impacting the company's market outlook.
- Investor Attention: Pomerantz LLP is investigating whether Atara and its executives engaged in securities fraud or other unlawful business practices, advising investors to contact the firm for more information, which may lead to a class action lawsuit.
- Potential Legal Consequences: This investigation could expose Atara to legal liabilities, further affecting shareholder confidence and market performance, prompting investors to closely monitor future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.150
Low
18.00
Averages
21.50
High
25.00
Current: 9.150
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atara Biotherapeutics Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to significant financial losses for investors and negatively impacted the company's reputation and market confidence.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and expertise in the field, urging investors to choose qualified legal counsel wisely.
- Investor Rights Protection: Until the class action is certified, investors can choose to retain or change their legal counsel, and their ability to share in any potential future recovery is not dependent on serving as lead plaintiff, ensuring every investor has the opportunity to participate in potential compensation.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Atara Biotherapeutics on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, alleging the company failed to disclose critical adverse information that may have led to investor losses.
- Allegation Details: The lawsuit claims that Atara issued false and misleading statements regarding its business and prospects, particularly overstating the regulatory outlook for the tabelecleucel Biologics License Application, while manufacturing issues heightened the risk of FDA scrutiny and jeopardized ongoing clinical trials.
- Investor Action: Affected investors must apply by May 22, 2026, to be appointed as lead plaintiff in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for assistance.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in shareholder rights, with extensive experience in securities, derivative, and commercial litigation, dedicated to safeguarding investors' legal interests.
See More
Reminder for Atara Biotherapeutics Investors on Class Action Deadline
- FDA Response Letter Impact: On January 16, 2025, Atara received a Complete Response Letter from the FDA, causing its stock to plummet by $5.33, or 40.5%, indicating that its application for the Epstein-Barr treatment would not be approved, severely undermining investor confidence.
- Clinical Hold Imposed: On January 21, 2025, Atara disclosed that the FDA had placed a clinical hold on its IND applications due to GMP compliance issues, resulting in a further stock decline of $0.52, or 7.9%, highlighting the increasing regulatory risks faced by the company.
- Second Response Letter Issued: On January 12, 2026, Atara disclosed another Complete Response Letter from the FDA regarding its resubmitted application, leading to a stock drop of $7.79, or 56.99%, exacerbating investor losses and signaling ongoing challenges in regulatory approval.
- Class Action Context: The class action lawsuit alleges that Atara failed to disclose critical manufacturing issues and deficiencies in clinical trials throughout the class period, leading to a misrepresentation of the company's prospects and potentially significant negative impacts on its financial condition.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Class Action: Lufax Holding Ltd. faces a class action for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, for affected investors.
- Atara Biotherapeutics Risks: Atara Biotherapeutics, Inc. is under scrutiny for undisclosed manufacturing issues and clinical trial risks that may hinder FDA approval from May 20, 2024, to January 9, 2026, with a lead plaintiff deadline of May 22, 2026.
- Coty Performance Decline: Coty Inc. is implicated in a class action due to underperformance in its Consumer Beauty segment and slowing market growth from May 7, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026.
- Legal Consultation Advisory: The Law Offices of Frank R. Cruz advise investors who suffered losses during these periods to seek legal counsel to understand their rights and ensure their interests are represented in the class actions.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- False Statements Allegation: The complaint claims that the defendants failed to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the likelihood of FDA approval for tabelecleucel, thereby significantly impacting Atara's business and financial condition.
- Investor Action: Affected investors have until May 22, 2026, to request to be appointed as lead plaintiff in the lawsuit, allowing them to seek compensation without needing to serve as lead plaintiff to share in any recovery.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors nationwide, underscoring its commitment to restoring investor capital and ensuring corporate accountability.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws.
- Regulatory Scrutiny: Atara's Biologics License Application for tabelecleucel faced a Complete Response Letter from the FDA due to manufacturing issues, resulting in a 40.5% stock price drop on January 16, 2025, highlighting significant regulatory risks.
- Clinical Trials Halted: The FDA placed a clinical hold on Atara's active IND applications due to unresolved GMP compliance issues identified during inspections, raising further concerns about the company's product development capabilities.
- Stock Price Volatility: On January 12, 2026, Atara received another Complete Response Letter from the FDA, causing a 56.99% decline in stock price, indicating a severe loss of investor confidence in the company's future prospects.
See More
Atara Biotherapeutics Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to significant financial losses for investors and negatively impacted the company's reputation and market confidence.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and expertise in the field, urging investors to choose qualified legal counsel wisely.
- Investor Rights Protection: Until the class action is certified, investors can choose to retain or change their legal counsel, and their ability to share in any potential future recovery is not dependent on serving as lead plaintiff, ensuring every investor has the opportunity to participate in potential compensation.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Atara Biotherapeutics on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, alleging the company failed to disclose critical adverse information that may have led to investor losses.
- Allegation Details: The lawsuit claims that Atara issued false and misleading statements regarding its business and prospects, particularly overstating the regulatory outlook for the tabelecleucel Biologics License Application, while manufacturing issues heightened the risk of FDA scrutiny and jeopardized ongoing clinical trials.
- Investor Action: Affected investors must apply by May 22, 2026, to be appointed as lead plaintiff in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for assistance.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in shareholder rights, with extensive experience in securities, derivative, and commercial litigation, dedicated to safeguarding investors' legal interests.
See More
Reminder for Atara Biotherapeutics Investors on Class Action Deadline
- FDA Response Letter Impact: On January 16, 2025, Atara received a Complete Response Letter from the FDA, causing its stock to plummet by $5.33, or 40.5%, indicating that its application for the Epstein-Barr treatment would not be approved, severely undermining investor confidence.
- Clinical Hold Imposed: On January 21, 2025, Atara disclosed that the FDA had placed a clinical hold on its IND applications due to GMP compliance issues, resulting in a further stock decline of $0.52, or 7.9%, highlighting the increasing regulatory risks faced by the company.
- Second Response Letter Issued: On January 12, 2026, Atara disclosed another Complete Response Letter from the FDA regarding its resubmitted application, leading to a stock drop of $7.79, or 56.99%, exacerbating investor losses and signaling ongoing challenges in regulatory approval.
- Class Action Context: The class action lawsuit alleges that Atara failed to disclose critical manufacturing issues and deficiencies in clinical trials throughout the class period, leading to a misrepresentation of the company's prospects and potentially significant negative impacts on its financial condition.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Class Action: Lufax Holding Ltd. faces a class action for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, for affected investors.
- Atara Biotherapeutics Risks: Atara Biotherapeutics, Inc. is under scrutiny for undisclosed manufacturing issues and clinical trial risks that may hinder FDA approval from May 20, 2024, to January 9, 2026, with a lead plaintiff deadline of May 22, 2026.
- Coty Performance Decline: Coty Inc. is implicated in a class action due to underperformance in its Consumer Beauty segment and slowing market growth from May 7, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026.
- Legal Consultation Advisory: The Law Offices of Frank R. Cruz advise investors who suffered losses during these periods to seek legal counsel to understand their rights and ensure their interests are represented in the class actions.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- False Statements Allegation: The complaint claims that the defendants failed to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the likelihood of FDA approval for tabelecleucel, thereby significantly impacting Atara's business and financial condition.
- Investor Action: Affected investors have until May 22, 2026, to request to be appointed as lead plaintiff in the lawsuit, allowing them to seek compensation without needing to serve as lead plaintiff to share in any recovery.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors nationwide, underscoring its commitment to restoring investor capital and ensuring corporate accountability.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws.
- Regulatory Scrutiny: Atara's Biologics License Application for tabelecleucel faced a Complete Response Letter from the FDA due to manufacturing issues, resulting in a 40.5% stock price drop on January 16, 2025, highlighting significant regulatory risks.
- Clinical Trials Halted: The FDA placed a clinical hold on Atara's active IND applications due to unresolved GMP compliance issues identified during inspections, raising further concerns about the company's product development capabilities.
- Stock Price Volatility: On January 12, 2026, Atara received another Complete Response Letter from the FDA, causing a 56.99% decline in stock price, indicating a severe loss of investor confidence in the company's future prospects.
See More
